Evaluation of treatment satisfaction after switching from topical steroid to delgocitinib ointment-dominated treatment for skin rashes on the trunk and limbs in atopic dermatitis.

Abe Masatoshi0 个研究点目标入组 100 人开始时间: 2023年5月29日最近更新: 2024年5月27日

适应症

试验速览

暂无简介。

•(1) Patients aged 18 years and older with atopic dermatitis when obtaining consent.
•(2) Patients using topical steroids for trunk or limb rash for more than 3 months.
•(3) Patients with local side effects such as skin atrophy or telangiectasia due to the use of topical steroids on the trunk or limb or who are expected to use topical steroids for a long time and are concerned about the development of local side effects.
•(4) Patients whose trunk and limbs are being treated with topical steroids and are considered treatable with a maximum of 5 g of delgocitinib ointment per dose (within approximately 30% of body surface area, taking into account body size).
•(5) Patients who have given written consent to participate in the study.
•**: Any rank and formulation of topical steroids.

•(1) Patients using the strongest topical steroids. Using clobetasol propionate shampoo on the scalp is allowed.
•(2) Patients using delgocitinib ointment or difamilast ointment.
•(3) Patients with plaque or other erosions forming obvious foci at the site of application of studied drug.
•(4) Patients who are pregnant, may become pregnant, or plan to become pregnant during the study period.
•(5) Patients who are breastfeeding
•(6) Patients previously treated with delgocitinib ointment
•(7) Patients receiving systemic therapy with internal medications (steroids, cyclosporine, JAK inhibitors) at the time of obtaining consent or within the last 3 months.
•(8) Patients receiving systemic therapy with biologics (e.g., dupilumab, nemolizumab) at the time of obtaining consent or within the last 6 months
•(9) Patients receiving phototherapy, such as ultraviolet light therapy, at the time of obtaining consent or within the last 3 months.
•(10) Patients who have participated in a clinical trial or similar within the last 6 months
•(11) Patients deemed ineligible for the study by the investigator or others.

发起方

Abe Masatoshi